CLPT at a glance
ClearPoint Neuro, Inc. (CLPT, SEC CIK 1285550) filed its latest 10-K annual report on March 17, 2026, a 10-Q quarterly report on October 28, 2026, an 8-K current report on November 18, 2026 and Form 4 insider filings as recently as October 2, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), ClearPoint Neuro, Inc. (CLPT) reported revenue of $37.0 million (up 17.8% from FY2024) and a net loss of $25.5 million. Diluted EPS was -$0.90.
- As of September 30, 2026, 19 institutional investment managers tracked by SignalX reported holding ClearPoint Neuro, Inc. (CLPT) shares worth $73.6 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $37.0M
- +17.8% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 19 funds
- $73.6M · −2 vs prior quarter
- Latest 8-K
- Nov 18, 2026
- Item 1.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- New risk: CAL preclinical CRO facility investment, triggered by ongoing build-out and operations
- Operational risk: construction, permitting, equipment, or vendor delays could restrict CAL capacity and service offerings
- Regulatory risk: failure to achieve or maintain GLP compliance could prevent GLP study performance
- Market risk: insufficient customer demand or delayed statements of work could leave CAL underutilized
- Financial risk: CAL lease expires approximately eleven years after final premises delivery, with fixed rent and annual increases
Management Discussion & Analysis
- Q3 revenue $12.1M, up 36% YoY from $8.9M
- Gross margin 58% vs 63% YoY, with gross profit $7.1M vs $5.6M
- Best segment: neurosurgery navigation and therapy revenue $5.4M, up 59% YoY
- Worst segment: biologics disposable products $1.2M, down 8% YoY
- Cash $46.2M; nine-month operating cash use $20.1M, ATM proceeds $22.0M supporting liquidity for at least twelve months
AI summary of the CLPT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 1.01: Entry into a Material Definitive Agreement
- ATM equity capacity increased from $50 million to $150 million, expanding potential financing flexibility
- Approximately $22.5 million sold, leaving roughly $27.5 million currently available under the existing prospectus
Item EX-99.1: Item EX-99.1
- Q3 revenue $12.1M, up 36% year over year, with growth outpacing operating-expense growth of 23%
- Neurosurgery navigation and therapy revenue $5.4M, up 59%, primarily reflecting IRRAflow sales after the IRRAS acquisition
Item EX-99.2: Item EX-99.2
- Investor presentation outlines 2026 strategy, expanding from four to five growth pillars with commercial cell and gene therapy delivery
- 2026 revenue guidance of $48.0-$50.0 million, versus $37.0 million in 2025
Item 2.02: Results of Operations and Financial Condition
- Q3 fiscal 2026 results announced for the quarter ended September 30, 2026
- Full financial details and management commentary contained in Exhibit 99.1
Item 7.01: Regulation FD Disclosure
- Updated investor presentation posted October 28, 2026, signaling refreshed messaging for analysts and investors
- Presentation available as Exhibit 99.2 and intended for use in future investor communications
Item EX-99.1: Item EX-99.1
- Q2 revenue $10.9M, up 18% YoY, driven by neurosurgery navigation and therapy revenue growth of 62% to $5.6M
- Biologics and drug delivery revenue fell 15% to $4.0M, reflecting lower biopharma trial-related product shipments
Item EX-99.2: Item EX-99.2
- Investor presentation outlines a five-pillar strategy targeting $500m revenue, adding commercial drug delivery to four existing businesses
- 2026 revenue guidance $48.0m-$52.0m, versus $37.0m in 2025
Item 7.01: Regulation FD Disclosure
- Updated investor presentation furnished as Exhibit 99.2, signaling refreshed messaging for investors and analysts
- Presentation available on ClearPoint Neuro’s investor-relations website for review
Item 2.02: Results of Operations and Financial Condition
- Q2 fiscal 2026 financial results for quarter ended June 30, 2026 announced
- Full revenue, earnings and operating details in Exhibit 99.1 press release
AI summaries of CLPT 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for CLPT
Don't miss the next CLPT filing
- Alerts as it files. A push when CLPT files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut CLPT, by share count.
- Ask anything. An AI agent that reads every CLPT filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| FLETCHER R JOHN | A | Oct 1, 2026 | 993 | $12.21 |
| Richards Timothy T. | A | Oct 1, 2026 | 319 | $12.21 |
| BURNETT JOSEPH | M | Sep 2, 2026 | 12,517 | - |
| BURNETT JOSEPH | M | Sep 2, 2026 | 12,517 | $3.47 |
| FLETCHER R JOHN | A | Jul 1, 2026 | 662 | $17.84 |
| Richards Timothy T. | A | Jul 1, 2026 | 222 | $17.84 |
| BURNETT JOSEPH | A | Jun 30, 2026 | 1,361 | $11.93 |
| D'Alessandro Danilo | A | Jun 30, 2026 | 1,085 | $11.93 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $31.4M | $37.0M |
| Gross Profit | - | $19.1M | $22.7M |
| Operating Income | - | -$19.7M | -$24.2M |
| Net Income | - | -$18.9M | -$25.5M |
| Gross Margin | - | 60.9% | 61.4% |
| Op. Margin | - | -62.9% | -65.4% |
| Net Margin | - | -60.3% | -69.1% |
| Balance Sheet | |||
| Total Assets | $42.7M | $39.2M | $97.7M |
| Equity | - | $25.4M | $28.0M |
| ROE | - | -74.5% | -91.1% |
| Per Share | |||
| EPS | - | $-0.70 | $-0.90 |
| Cash Flow | |||
| Operating CF | - | -$8.9M | -$23.9M |
| CapEx | $717K | $275K | $522K |
Source: XBRL data in ClearPoint Neuro, Inc. (CLPT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate CLPT share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 19 | $73.6M |
| Q2 2026 | 21 | $108.9M |
| Q1 2026 | 20 | $53.5M |
| Q4 2025 | 22 | $88.0M |
| Q3 2025 | 19 | $119.5M |
| Q2 2025 | 21 | $63.2M |
| Q1 2025 | 14 | $36.9M |
| Q4 2024 | 11 | $37.1M |
- Goldman Sachs Group+211.3K (+152%)
- Bank of America Corp+116.9K (+149%)
- State Street Corp+59.0K (+7%)
- Citigroup+50.8K (+384%)
- Citadel Advisors LLC+33.3K (+68%)
- BlackRock−233.0K (-10%)
- Millennium Management−116.0K (-32%)
- Morgan Stanley−17.5K (-11%)
- Wells Fargo & Co−17.1K (-66%)
- Vanguard Capital Management LLC−1.8K (-0%)
- AQR Capital Management+12.3K
- Two Sigma Investments−154.9K
- Raymond James Financial−22.4K
- FMR LLC (Fidelity)−9.5K
Source: 13F-HR filings on SEC EDGAR (aggregated from 147 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
CLPT filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 18, 2026 | - | Analysis | - |
| 8-K | Oct 28, 2026 | - | Analysis | - |
| 10-Q | Oct 28, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 8-K | Aug 3, 2026 | - | Analysis | - |
| 10-Q | Aug 3, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 2, 2026 | - | - | |
| 4 | May 26, 2026 | - | - | |
| 4 | May 26, 2026 | - | - | |
| 4 | May 26, 2026 | - | - | |
| 4 | May 26, 2026 | - | - | |
| 4 | May 26, 2026 | - | - | |
| 4 | May 26, 2026 | - | - | |
| 4 | May 21, 2026 | - | - | |
| 4 | May 21, 2026 | - | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
CLPT SEC filings: frequently asked questions
Which institutions hold CLPT stock?
As of September 30, 2026, the largest ClearPoint Neuro, Inc. (CLPT) holders among the 13F filers tracked by SignalX were BlackRock ($26.2 million), Vanguard Capital Management LLC ($15.0 million), State Street Corp ($10.7 million), Goldman Sachs Group ($4.3 million), Millennium Management ($3.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was CLPT's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), ClearPoint Neuro, Inc. (CLPT) reported revenue of $37.0 million (up 17.8% from FY2024) and a net loss of $25.5 million. Diluted EPS was -$0.90. The figures come from the XBRL data in the 10-K.
What did CLPT report in its latest 8-K?
ClearPoint Neuro, Inc. (CLPT) filed an 8-K on November 18, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). ATM equity capacity increased from $50 million to $150 million, expanding potential financing flexibility.
What are the latest CLPT SEC filings?
ClearPoint Neuro, Inc. (CLPT) filed its latest 10-K annual report on March 17, 2026, a 10-Q quarterly report on October 28, 2026, an 8-K current report on November 18, 2026 and a Form 4 insider filing on October 2, 2026.
What is CLPT's SEC CIK number?
ClearPoint Neuro, Inc. (CLPT)'s SEC Central Index Key (CIK) is 1285550. EDGAR lists every CLPT filing under that number.
Ask anything about CLPT
The research agent reads CLPT's filings, financials, insider trades and 13F holders, then answers with sources.